FTSE MIB
32.797,20 +131,99 (+0,40%) Dow Jones
38.529,84 -59,32 (-0,15%) Nasdaq
17.667,98 -20,91 (-0,12%) Nikkei 225
38.102,44 -712,12 (-1,83%) Petrolio
79,20 +0,75 (+0,96%) Bitcoin EUR
61.042,80 -1.152,75 (-1,85%)
RARE Jul 2024 50.000 call
| Chiusura precedente | 0,8500 |
| Aperto | 0,8500 |
| Denaro | 0,0000 |
| Domanda | 0,0000 |
| Prezzo d'esercizio | 50,00 |
| Scadenza | 2024-07-19 |
| Min-Max giorno | 0,8500 - 0,8500 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 243 |
GlobeNewswireUltragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease
Treatment with setrusumab (UX143) for at least 6 months resulted in 67% reduction in annualized fracture rate in patients with OI in Phase 2/3 Orbit studyQuantitative data from the Phase 1/2 study of GTX-102 for AS show clinically meaningful improvements in multiple domains as compared to natural history4 of 5 patients in lowest-dose cohort of Phase 1/2/3 study of UX701 in Wilson disease are tapering off of chelators and/or zinc therapy, including 2 that are now completely off standard therapyUl
- GlobeNewswire
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral density (BMD) Ultragenyx hosting Analyst Day on Monday, October 16 at 8:30 a.m. ET NOVATO, Calif., VANCOUVER, British Columbia and LONDON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) today announced interim data from the Phase
- GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 80,366 restricted stock units of the company’s common stock and the grant of non-qualified stock options to purchase an aggregate of 140,469 shares of common stock of the company to Howard Horn, its newly appointed Chief Financial Officer and Exe
